The company’s flagship product is the Aura6000, an implanted hypoglossal nerve stimulator for sleep apnea that won FDA investigational device exemption in November 2014.
ImThera Medical has already raised $2.7 million from 29 investors, according to the SEC filing from the San Diego, Calif.-based company. No investors were named, and the company has not commented on the funding round.
The Aura6000 system uses 2 implanted components, 1 near the collarbone and 1 in the upper neck. The therapy uses a multi-contact electrode and programmable pulse generator to improve muscle tone in certain tongue muscles to help control upper airway flow and reduce or eliminate sleep apnea, according to the company’s website.
In May, ImThera said the 1st 2 U.S. patients were successfully implanted with the device for a clinical study of its Aura6000 system.
ImThera’s Aura6000 has already received CE Mark clearance in Europe and is currently commercially available in certain markets outside the U.S., the company said.